Search

e90 Volume 35 Number 8S to study the availability of information about the studied population, clinical experience, pharmacokinetic properties, and drug–drug interactions. Using the Systematic Information for Monitoring score, available information was considered clinically applicable if it provided information that could be applied in clinical practice. Missing information was either a statement that information was absent, unjustifiably nonavailable information, or hollow statements (eg, “caution in older patients”). Descriptive statistics (frequencies) were applied using SPSS 20.0. Results: The availability of relevant and clinically applicable information ranged between 10% (Belgian Repertorium and BNF) and 20% (FK), except for the PL (mean, 66%). The PL, which is comparable to the European SmPC, appeared a more extensive document (7–32 pages) than the other handbooks (2 pages). In the handbooks, most information was present about drug–drug interactions (range, 30%–75%). Information about patient characteristics and about experience in older people was present in < 7% of the handbook texts, except for the PL (48% and 81%, respectively). Clinically applicable information (what to monitor, critical value, how to respond) concerning renal impairment ranged from 4% to 29%. Conclusion: This study found that the availability and clinical applicability of information about older people for rational prescribing of medicines is incomplete in the investigated European and American handbooks. Because these handbooks are the primary documents that guide prescribing in actual medical practice, the availability and clinical applicability of the information on older individuals should be improved. Disclosure of Interest: J. Boer: None declared. E. Beers: Grant/ research support from: Erna Beers has received a grant of the Dutch Society of Clinical Pharmacology & Biopharmacy (NVKF&B) for her training in clinical pharmacology and therapeutics. This manuscript was written in the context of her training. The Expertise Centre Pharmacotherapy in Old Persons (EPHOR) is financially supported by The Netherlands Organisation for Health Research and Development (ZonMW). The authors’ work was independent of the NVKF&B and ZonMW. T. Egberts: None declared. H. Leufkens: None declared. P. Jansen: Grant/research support from: The Expertise Centre Pharmacotherapy in Old Persons (EPHOR) is financially supported by The Netherlands Organisation for Health Research and Development (ZonMW).